{NAME}, its ordinary moments like this

That change the future [That change the future]( [MDA - Muscular Dystrophy Association]( [Donate Now]( [Let’s make every moment count!]( Dear {NAME}, The FDA’s approval of ELEVIDYS to treat Duchenne muscular dystrophy (DMD) was a historic moment for everyone in the neuromuscular disease community. Now, many families whose child is diagnosed with DMD have an unprecedented treatment option that can stop this fatal disease. What researchers have learned in creating ELEVIDYS could also lead to significant breakthroughs in treating other diseases, giving hope to even more families. It was a historic moment. But it was based on millions of moments just like this—ordinary days when researchers took one more step forward and caring people like you made a gift to support them. Will you make today another one of those moments? [Your next gift]( will advance research, advocacy, and patient programs that help people with neuromuscular diseases live longer, more independent lives. “People should support MDA because they have made such a difference,” says Jessica, whose son Conner participated in the ELEVIDYS clinical trial. “The MDA is the reason why Conner and so many other boys are treated right now and will be treated.” Thank you for your generosity! Making every moment count, [Jeremy Signature] Jeremy Kraut-Ordover, CFRE Chief Development & Growth Officer [I'LL GIVE NOW]( [Forward this email to a friend!]( [MDA - Muscular Dystrophy Association]( [Donate Now]( [Facebook]( [Twitter]( [YouTube]( [Instagram]( [LinkedIn]( © 2023 Muscular Dystrophy Association All rights reserved. Muscular Dystrophy Association 161 N. Clark, Suite 3550 Chicago, IL 60601, US | 1-800-572-1717 [Unsubscribe]( | [State Fundraising Notice]( The Muscular Dystrophy Association (MDA) is a qualified 501(c)(3) tax-exempt organization. [View Online]( | [Privacy Policy](